TRVI

Trevi Therapeutics (TRVI)

About Trevi Therapeutics (TRVI)

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.

Details

Daily high

$10.71

Daily low

$10.25

Price at open

52 Week High

$14.39

52 Week Low

$4.85

Market cap

1.4B

Dividend yield

0.00%

Volume

744

Avg. volume

1.4M

P/E ratio

-33.17

Trevi Therapeutics News